Department of Public Health, Research Unit for General Practice, Aarhus University, Bartholins Allé 2, 8000, Aarhus C, Denmark.
Department of Public Health, Research Centre for Cancer Diagnosis in Primary Care, Aarhus University, Bartholins Allé 2, 8000, Aarhus C, Denmark.
Br J Cancer. 2018 Aug;119(4):471-479. doi: 10.1038/s41416-018-0178-7. Epub 2018 Aug 1.
Around 50% of individuals with colorectal cancer (CRC) initially present with non-alarm symptoms.
We investigated the value of using the faecal immunochemical test (FIT) in the diagnostic process of CRC and other serious bowel disease in individuals presenting with non-alarm symptoms in general practice. The study was conducted in the Central Denmark Region from 1 September 2015 to 30 August 2016. The FIT was used as a rule-in test on patients aged ≥30 years with non-alarm symptoms of CRC. The cut-off value was set to 10 µg Hb/g faeces.
A total of 3462 valid FITs were performed. Of these, 540 (15.6%) were positive. Three months after FIT performance, 51 (PPV: 9.4% (95% CI: 7.0;11.9)) individuals with a positive FIT were diagnosed with CRC and 73 (PPV: 13.5% (95%CI: 10.6;16.4)) with other serious bowel disease. Of CRCs, 66.7% were diagnosed in UICC stage I & II and 19.6% in stage IV. The false negative rate for CRC was <0.1% for the initial 3 months after FIT performance.
The FIT may be used as a supplementary diagnostic test in the diagnostic process of CRC and other serious bowel disease in individuals with non-alarm symptoms of CRC in general practice.
约 50%的结直肠癌（CRC）患者最初表现为非报警症状。
我们研究了在一般实践中出现非报警症状的个体中使用粪便免疫化学检测（FIT）在 CRC 和其他严重肠道疾病的诊断过程中的价值。该研究于 2015 年 9 月 1 日至 2016 年 8 月 30 日在丹麦中部地区进行。FIT 被用作≥30 岁非报警 CRC 症状患者的诊断性检测。将截止值设定为 10μg Hb/g 粪便。
共进行了 3462 次有效的 FIT 检测。其中，540 次（15.6%）为阳性。在 FIT 检测后 3 个月，51 名（阳性预测值：9.4%（95%CI：7.0；11.9））FIT 阳性患者被诊断为 CRC，73 名（阳性预测值：13.5%（95%CI：10.6；16.4））被诊断为其他严重肠道疾病。在 CRC 中，66.7%为 UICC Ⅰ和Ⅱ期，19.6%为Ⅳ期。FIT 检测后 3 个月内，CRC 的假阴性率<0.1%。
在一般实践中出现非报警 CRC 症状的个体中，FIT 可作为 CRC 和其他严重肠道疾病诊断过程中的辅助诊断检测。
